What the name refers to
A type I and II 5-alpha-reductase inhibitor authorised for benign prostatic hyperplasia; hair-loss approval varies by country.
Evidence and regulatory context
At least one regulated medicine or indication exists for this active ingredient. Authorisation is tied to a particular formulation, manufacturer, indication and jurisdiction; it does not validate unrelated products using the same name.
Reading product records
Route, vehicle and concentration can materially change a topical product. A page about an approved oral or ophthalmic medicine does not automatically validate a compounded hair formulation or an unapproved research product using the same active ingredient.
Primary research links
Use current regulator and study records rather than treating a catalogue description as medical evidence.